Replimune Group REPL Research and development incentives
Research and development incentives at other companies
Other financials
Where this comes from
Reported directly by Replimune Group in its filing.
Tagged under the XBRL concept repl:ResearchAndDevelopmentIncentivesIncome.
The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →
Ask your AI about Replimune Group's research and development incentives.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Replimune Group's research and development incentives?
- Replimune Group (REPL) reported research and development incentives of $341K in Q4 2025.
- How has Replimune Group's research and development incentives changed year-over-year?
- Replimune Group's research and development incentives decreased by 9.3% year-over-year, from $376K to $341K.
- What is the long-term trend for Replimune Group's research and development incentives?
- Over 3 years (2022 to 2025), Replimune Group's research and development incentives has grown at a -17.6% compound annual growth rate (CAGR), from $3.17M to $1.77M.
- What does research and development incentives mean?
- This metric represents government grants, tax credits, or other financial subsidies received to offset the costs associated with clinical trials and drug development activities. It reflects the company's ability to leverage external funding mechanisms to reduce the net financial burden of its research pipeline. Monitoring this helps investors understand the extent to which non-dilutive capital supports the company's innovation efforts.